Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04965766
Status:
RECRUITING
Last Update Posted:
2023-05-18
First Post:
2021-06-03
Brief Title:
Patritumab Deruxtecan U3-1402 in Unresectable Locally Advanced or Metastatic Breast Cancer
Sponsor:
Gustave Roussy Cancer Campus Grand Paris
Organization:
Gustave Roussy Cancer Campus Grand Paris
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Metastatic Breast Cancer |
Keywords:
| Name | View |
|---|---|
| HER3-DXd | View |
| Metastatic breast cancer | View |
| Advanced breast cancer | View |
| Unresectable breast cancer | View |
| HER2- Breast Cancer | View |
| Hormone-receptor positive breast cancer | View |
| HR breast cancer | View |
| Antibody drug conjugate | View |
| ADC | View |
| Patritumab deruxtecan | View |
| U3-1402 | View |
| Refractory metastatic breast cancer | View |
| HER2 Negative | View |
| MBC | View |
| ABC | View |
| Metastatic BC | View |
| Advanced BC | View |
| Unresectable BC | View |
| Refractory advanced breast cancer | View |
| Refractory ABC | View |
| Refractory MBC | View |